期刊文献+

心脑血管药物不良反应200例分析及合理用药对策 被引量:10

200 cases of cardiovascular adverse drug reactions and countermeasures for rational use of drugs
在线阅读 下载PDF
导出
摘要 目的通过分析心脑血管药物不良反应,探讨治疗心脑血管疾病的合理用药对策。方法选取2012~2014年我院心脑血管疾病用药发生不良反应的200例患者为研究对象,运用数据挖掘方法,分析不良反应的类别与药物品种之间的关联,探讨不良反应发生的原因,提出优化心脑血管用药的对策。结果肝功能异常、肾功能损伤和呼吸系统异常是心脑血管药物常见的不良反应,多种药物合用更容易引发不良反应。药物本身缺乏靶向性和医生选用不合适的药物治疗是主要的诱因。结论心脑血管药物引发不良反应比较普遍,肝肾功能损伤和呼吸系统异常最常见;引发不良反应的主要原因是药物治疗缺乏靶向性,合理用药、用药个体化和增加药物治疗的靶向性是解决问题的关键。 Objective To analyze the cardiovascular adverse drug reactions in order to explore countermeasures for rational use of drugs. Methods 200 cases of cardiovascular adverse drug reactions between 2012 and 2014 were chosen as research objects. Data mining algorithm was used to analyze the categories of adverse reactions and the correlation between the reactions and drug varieties.The adverse reactions causes were investigated, and the countermeasures of optimizing cardiovascular medication were put forward.Results The common adverse reactions to cardiovascular drugs included liver dysfunction, renal function damage, and respiratory abnormalities. The mixed usage of drugs could more easily cause adverse reactions. The main reasons were the lack of drug targeting and the improper selection of drugs by doctors. Conclusion Cardiovascular drugs can cause adverse reactions in which liver and renal function damage and respiratory abnormalities are the most common. The main reason is the lack of drug targeting. Rational use of drugs, individualized drug use, and increasing drug targeting are countermeasures to solve the problem.
作者 薛彦宁
出处 《西南国防医药》 CAS 2016年第3期290-292,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 心脑血管 药物 不良反应 合理用药 cardiovascular drug adverse reaction rational drug use
  • 相关文献

参考文献7

二级参考文献51

  • 1浦波,陈影,曹艳华.心脑舒通胶囊治疗冠心病心绞痛临床观察[J].吉林医药学院学报,2005,26(2):85-87. 被引量:10
  • 2凌世长,田青,苏静怡,唐朝枢,汤健,霍勇,朱国英,赵明,彭师奇.精-甘-天-丝氨酸四肽修饰的脂质体作为药物载体导向溶栓的研究[J].北京医科大学学报,1994,26(3):174-177. 被引量:10
  • 3唐敏,戴勇,涂植光.原发性高血压基因机制研究进展[J].国际检验医学杂志,2006,27(1):61-64. 被引量:21
  • 4江国虹,李静,潘怡,郑文龙,杨溢.膳食、体力活动与慢性病关系的研究[J].中国慢性病预防与控制,2007,15(2):94-96. 被引量:41
  • 5D'Andrea G,D'Ambrosio RL,Di Perna P,et al.A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J].Blood,2005,105(2):645-649.
  • 6Li J,Wang S,Barone J,et al.Warfarin pharmacogenomics[J].PT,2009,34(8):422-427.
  • 7Wadelius M,Chen L Y,Erikssbn N,et al.Association of warfarin dose with genes involved in its action and metabolism[J].Hum Cenet,2007,121(1):23-34.
  • 8Jain S,Li Y,Patil S,et al.A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity[J].J Mol Med,2005,83(2):121-131.
  • 9Jin W,Liu Y,Sheng HH,et al.Single nucleotide polymorphisms in promoter of angiotensin Ⅱ type 1 receptor gene associated with essential hypertension and coronary heart disease in Chinese population[J].Acta Pharmacol Sin,2003,24(11):1083-1088.
  • 10Kamide K,Yang J,Matayoshi T,et al.Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J].Circ J,2009,73(4):732-740.

共引文献20

同被引文献55

引证文献10

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部